

Particulars	3 months ended 31.12.2012
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	-
Received during the quarter	-
Disposed of during the quarter	-
Remaining unsolved at the end of the quarter	-

SEGMENT REVENUE, RESULTS AND CAPITAL EMPLOYED

in ` million

Particulars	3 months ended 31.12.2012	3 months ended 30.9.2012	3 months ended 31.12.2011	9 months ended 31.12.2012	9 months ended 31.12.2011	Year ended 31.3.2012
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Segment Revenue						
(a) Pharmaceuticals	1,618.2	1,685.4	1,532.5	4,923.5	4,489.2	5,861.1
(b) Generics	157.1	148.4	142.1	462.8	433.3	573.1
(c) OTC	323.0	283.7	341.9	805.4	877.8	1,171.1
(d) Animal Health	237.1	256.8	206.7	713.4	614.0	837.6
Total Income from Operations (Net)	2,335.4	2,374.3	2,223.2	6,905.1	6,414.3	8,442.9
2. Segment Results						
(a) Pharmaceuticals	155.8	323.9	333.6	686.2	1,106.1	1,292.3
(b) Generics	76.8	41.4	57.5	175.1	155.0	190.4
(c) OTC	57.8	51.2	71.1	107.0	147.0	175.2
(d) Animal Health	6.1	13.7	14.3	26.6	54.7	74.9
Total	296.5	430.2	476.5	994.9	1,462.8	1,732.8
Add/(Less):						
(a) Finance Costs	(4.6)	(0.4)	(0.6)	(5.8)	(3.2)	(5.4)
(b) Other Unallocable Expenditure	(72.9)	(45.7)	(104.4)	(201.5)	(236.4)	(296.4)
(c) Other Unallocable Income	197.8	199.5	189.1	609.0	546.7	815.9
Profit from Ordinary Activities before Tax	416.8	583.6	560.6	1,396.6	1,769.9	2,246.9
3. Capital Employed (Segment Assets less Segment Liabilities)						
(a) Pharmaceuticals	238.1	470.3	53.9	238.1	53.9	142.4
(b) Generics	62.3	60.3	56.3	62.3	56.3	42.6
(c) OTC	(18.7)	27.8	6.1	(18.7)	6.1	(27.3)
(d) Animal Health	291.8	295.3	240.0	291.8	240.0	254.6
Total	573.5	853.7	356.3	573.5	356.3	412.3
Add: Unallocable Corporate Assets less Unallocable Corporate Liabilities	8,558.4	7,988.2	7,864.6	8,558.4	7,864.6	7,766.4
Total Capital Employed	9,131.9	8,841.9	8,220.9	9,131.9	8,220.9	8,178.7

Notes:

- The above results were reviewed by the Audit Committee at its meeting held on 23rd January 2013 and approved at the meeting of the Board of Directors held on that date.
- The results for the quarter ended 31st December 2012 have been subjected to limited review by the statutory auditors of the company.
- Figures for the prior periods have been regrouped where necessary.

By Order of the Board

Ranjit Shahani
Vice Chairman and Managing Director
Mumbai, 23rd January 2013